The future of medical cannabis development in Europe
European Pharmaceutical Review
JULY 13, 2023
1,2 Moreover, except for countries such as Czechia, Denmark and Germany, the cost of these medications is borne by the patient, rather than national insurance or healthcare systems. This could lead to significant research waste. 1,2 Yet the pace of adoption in Europe has notably lagged countries such as Canada, Australia and the US.
Let's personalize your content